Research Guide | Triple Agonist Peptide
What Is Retatrutide? — Triple Receptor Agonist Research Guide
Retatrutide (LY3437943) is a synthetic peptide studied as a GLP-1/GIP/glucagon triple receptor agonist — the first compound in its class to simultaneously activate all three metabolic receptor targets. This guide covers its mechanism, receptor pharmacology, clinical research data, and sourcing for laboratory use.
What Is Retatrutide?
Retatrutide (development code LY3437943, also referred to as GLP-3 Reta in some research shorthand) is a synthetic peptide developed by Eli Lilly as an investigational compound. It is classified as a triple receptor agonist because it simultaneously activates three distinct G protein-coupled receptors central to metabolic regulation: the glucagon-like peptide-1 receptor (GLP-1R), the glucose-dependent insulinotropic polypeptide receptor (GIPR), and the glucagon receptor (GCGR).
This triple-receptor activation profile is what distinguishes retatrutide from all other current and investigational metabolic peptides. Semaglutide activates only GLP-1R. Tirzepatide activates GLP-1R and GIPR (dual agonist). Retatrutide adds GCGR to this dual foundation, creating a mechanistically unique compound that has generated significant interest in metabolic and hepatic research.
Retatrutide Mechanism of Action
GLP-1 Receptor (GLP-1R) — Primary Incretin Pathway
GLP-1R activation is the shared mechanism of the entire incretin peptide class. GLP-1 (glucagon-like peptide-1) is released from intestinal L-cells in response to nutrient intake. At the pancreatic beta cell, GLP-1R activation stimulates glucose-dependent insulin secretion via cAMP-mediated pathways. At the alpha cell, it suppresses inappropriate glucagon secretion. Centrally, GLP-1R activation in the hypothalamus and vagal afferents produces satiety signaling. Gastric emptying is slowed, reducing postprandial glucose excursions.
GIP Receptor (GIPR) — Amplification and Tolerability
GIP (glucose-dependent insulinotropic polypeptide) is the second incretin hormone. GIPR activation amplifies insulin secretion, signals in adipose tissue to enhance fatty acid storage regulation, and appears to modulate nausea responses to GLP-1R agonism. Adding GIPR activation (as tirzepatide did over semaglutide) was associated with enhanced metabolic efficacy in comparative trials. Retatrutide includes this dual incretin activation as its baseline.
Glucagon Receptor (GCGR) — The Triple Agonist Differentiator
GCGR activation is what makes retatrutide mechanistically unique. Glucagon receptor activation normally increases hepatic glucose output and drives lipolysis in adipose tissue. In isolation, this would be counterproductive for metabolic research involving glucose management. However, in the context of simultaneous GLP-1R and GIPR agonism, the insulinotropic counterbalancing effect of both incretin receptors preserves glycemic stability while the thermogenic, lipolytic, and hepatic effects of GCGR activation are maintained. The result is a net increase in energy expenditure and enhanced lipid mobilization on top of the incretin effects.
Key insight: The glucagon receptor was deliberately added to the incretin platform precisely because glucagon receptor agonism increases energy expenditure through thermogenic pathways — an effect neither GLP-1R nor GIPR agonism provides. This is why retatrutide consistently shows greater weight reduction in published data compared to tirzepatide and semaglutide.
Retatrutide vs Semaglutide vs Tirzepatide
| Compound | Class | Receptors | Peak Weight Loss Data |
|---|---|---|---|
| Semaglutide | GLP-1 mono-agonist | GLP-1R only | ~15% (72wk) |
| Tirzepatide | GLP-1/GIP dual agonist | GLP-1R + GIPR | ~22% (72wk) |
| Retatrutide | Triple agonist | GLP-1R + GIPR + GCGR | ~28.7% (68wk) |
Retatrutide in Laboratory Research
As a research-use-only compound, retatrutide is used in preclinical and in vitro laboratory settings to study:
- Multi-receptor metabolic pathway co-activation — examining how simultaneous GLP-1R, GIPR, and GCGR engagement differs from dual or single receptor activation
- Hepatic fat reduction mechanisms — Phase 2 data showed up to 82% liver fat reduction, making it a key compound for MASH/NAFLD pathway research
- Comparative incretin pharmacology — using retatrutide alongside tirzepatide and semaglutide to isolate receptor-specific contributions
- Energy expenditure pathway research — studying GCGR-mediated thermogenesis within a controlled incretin context
- Adipose tissue lipolysis signaling — GCGR effects on adipocyte lipid mobilization
Sourcing Retatrutide for Research
OligoPoly Laboratories supplies retatrutide as a lyophilized research peptide verified by independent third-party HPLC analysis (≥Independent Testing Required Before Release purity) with LC-MS molecular weight confirmation (theoretical MW: 4,731.33 g/mol) and a batch-specific Certificate of Analysis available via our online COA verification system. Ships from Houston, TX with 1–3 business day processing.
Related Research Resources
- Retatrutide vs Tirzepatide — Side-by-side receptor and efficacy comparison
- Retatrutide vs Semaglutide — Triple agonist vs GLP-1 monotherapy
- Triple Agonist Peptide Guide — Complete guide to the triple agonist research class
- GLP-1 Receptor Mechanism — In-depth GLP-1R pharmacology
- Metabolic Peptide Comparison Hub — Full metabolic research peptide index
Research Use Only: All compounds referenced on this page are strictly for laboratory and in vitro research purposes only. Not intended for human use, veterinary use, or diagnostic/treatment purposes. OligoPoly Laboratories sells research-grade peptides exclusively to qualified researchers.
Research Compounds Referenced in This Guide
For Research Use Only · Third-Party Tested · COA Verified · Ships from Houston TX